Investors should monitor upcoming data readouts from the Phase 2 atopic dermatitis trial and the ongoing Phase 3 PTCL trial. The extended cash runway reduces near-term dilution risk and supports multiple value inflection points through 2027.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $15.32entry
- T+1 · 8mo ago +2.61%α +1.59% · $15.72
- T+5 · 8mo ago −12.99%α −10.87% · $13.33
- T+20 · 7mo ago −0.98%α −4.57% · $15.17
- T+60 · 5mo ago −27.22%α −38.83% · $11.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic dermatitis trial data for soquelitinib, initiation of a Phase 2 trial in the same indication, and a successful $189 million public offering extending cash runway into Q2 2028. Despite increased R&D spending and a slight YoY increase in net loss, the company is advancing multiple clinical programs with upcoming data catalysts.
Key Financial Metrics
Key Facts
- Positive Phase 1 data in atopic dermatitis: 75% of soquelitinib patients achieved EASI 75 vs. 20% placebo; no severe adverse events.
- Initiated Phase 2 atopic dermatitis trial with ~200 patients; additional Phase 2 trials in asthma and hidradenitis suppurativa planned for 2026.
- Completed public offering raising $189.4 million in net proceeds, extending cash runway into Q2 2028.
- Cash, cash equivalents, and marketable securities: $56.8 million as of December 31, 2025 (excluding $189.4 million from January 2026 financing).
- R&D expenses increased to $33.7 million in 2025 from $19.4 million in 2024 due to clinical and manufacturing costs.
- Net loss for 2025 was $15.3 million vs. $62.3 million in 2024, a significant improvement despite higher operating costs.
Financial Impact
The $189.4 million financing significantly strengthens the balance sheet and funds operations into 2028. R&D spend increased 74% YoY to $33.7 million, reflecting accelerated development.
Risk Factors
- Clinical trial results may not replicate Phase 1 success, particularly in larger, more diverse populations.
- The company remains pre-revenue with no near-term path to profitability; valuation is entirely dependent on clinical outcomes.
- Dilution from the recent offering may pressure shares in the short term despite long-term runway benefits.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255077 |
Track record
15 reports on CRVS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers